High Avidity Anti-β2-Glycoprotein i Antibodies Activate Human Coronary Artery Endothelial Cells and Trigger Peripheral Blood Mononuclear Cell Migration
Free accessResearch articleFirst published online May, 2013
High Avidity Anti-β2-Glycoprotein i Antibodies Activate Human Coronary Artery Endothelial Cells and Trigger Peripheral Blood Mononuclear Cell Migration
Anti-β2-glycoprotein I antibodies (aβ2GPI) represent a potential pathogenic candidate for coronary artery diseases. High avidity aβ2GPI (HAv aβ2GPI) are known to be associated with thrombotic and obstetric manifestations in patients with antiphospholipid syndrome, who are also susceptible to the development of premature atherosclerosis. However, there is little information about how human coronary artery endothelial cells (HCAEC) are affected by HAv aβ2GPI. The purpose of our study was to evaluate the pathophysiological effects of HAv aβ2GPI on HCAEC and determine their influence on cytokine expression and migration of peripheral blood mononuclear cells. Following the two hit hypothesis, we co-stimulated HAv aβ2GPI-treated HCAEC in the presence and absence of the acute phase protein serum amyloid A (SAA). HAv aβ2GPI induced in vitro HCAEC dysfunction, through the ERK1/2 signaling pathway, promoted the expression of chemokines (MCP-1, GROα and IL-8) and IL-6, which led to the attraction and migration of peripheral blood mononuclear cells. These effects were potentiated and intensified in conditions with SAA, indicating that HAv aβ2GPI, in the presence of physiological concentrations of acute-phase proteins represent pathogenic autoantibodies, which could lead to the development of premature atherosclerosis and/or thrombosis development.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4:295–306.
2.
ShoenfeldYGerliRDoriaA. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation2005; 112:3337–47.
AdlerAAfekALevyYKerenGGeorgeJ. Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis. Nat Clin Pract Cardiovasc Med2009; 6:215–8.
5.
ArtenjakALakotaKFrankMCucnikSRozmanBBozicBShoenfeldYSodin-SemrlS. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev2012; 11:873–82.
6.
KasaharaHMatsuuraEKaiharaK. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol2005; 17:1533–42.
7.
CucnikSKvederTKrizajIRozmanBBozicB. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis2004; 63:1478–82.
8.
de LaatBDerksenRHde GrootPG. High-avidity anti-beta2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta2 glycoprotein I antibodies. J Thromb Haemost2006; 4:1619–21.
9.
ZagerUIrmanSLunderM. Immunochemical properties and pathological relevance of anti-beta2-glycoprotein I antibodies of different avidity. Int Immunol2011; 23:511–8.
10.
MeroniPLBorghiMORaschiETedescoF. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol2011; 7:330–9.
11.
CucnikSKvederTArtenjakA. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus2012; 21:764–5.
12.
SciasciaSRoccatelloDBerteroMT. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: A pilot study. Inflamm Res2012; 61:809–16.
13.
AmesPRAntinolfiICiampaA. Primary antiphospholipid syndrome: A low-grade auto-inflammatory disease?Rheumatology (Oxford)2008; 47:1832–7.
14.
Sodin-SemrlSZigonPCucnikSKvederTBlincATomsicMRozmanB. Serum amyloid A in autoimmune thrombosis. Autoimmun Rev2006; 6:21–7.
15.
Del PapaNShengYHRaschiE. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol1998; 160:5572–8.
16.
RaschiETestoniCBosisioDBorghiMOKoikeTMantovaniAMeroniPL. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood2003; 101:3495–500.
17.
HamidCNorgateKD'CruzDPKhamashtaMAArnoMPearsonJDFramptonGMurphyJJ. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel proinflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis2007; 66:1000–7.
18.
GeorgeJBlankMLevyYMeroniPDamianovichMTincaniAShoenfeldY. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation1998; 97:900–6.
19.
BlankMShoenfeldYCabillySHeldmanYFridkinMKatchalski-KatzirE. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA1999; 96:5164–8.
20.
AronovichRGurwitzDKloogYChapmanJ. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology2005; 210:781–8.
21.
AvcinTAmbrozicABozicBAccettoMKvederTRozmanB. Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol2002; 20:101–8.
22.
LakotaKMrak-PoljšakKRozmanBKvederTTomšičMSodin-SemrlS. Serum amyloid A activation of inflammatory and adhesion molecules in human coronary artery and umbilical vein endothelial cells. Eur J Inflamm2007; 5:73–81.
23.
MeroniPLRaschiETestoniC. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum2001; 44:2870–8.
24.
Del PapaNGuidaliLSalaA. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum1997; 40:551–61.
ClemensNFrauenknechtKKatzavASommerCvon LandenbergP. In vitro effects of antiphospholipid syndrome-IgG fractions and human monoclonal antiphospholipid IgG antibody on human umbilical vein endothelial cells and monocytes. Ann NY Acad Sci2009; 1173:805–13.
27.
Vega-OstertagMCasperKSwerlickRFerraraDHarrisENPierangeliSS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum2005; 52:1545–54.
28.
MullaMJBrosensJJChamleyLW. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol2009; 62:96–111.
29.
Lopez-PedreraCBuendiaPCuadradoMJ. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum2006; 54:301–11.
30.
ZhouHChenDXieHXiaLWangTYuanWYanJ. Activation of MAPKs in the anti-beta2GPI/beta2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. Thromb Res2012; 130:e229–35.
31.
SimonciniSSapetCCamoin-JauLBardinNHarleJRSampolJDignat-GeorgeFAnfossoF. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with antiphospholipid syndrome. Int Immunol2005; 17:489–500.
